Inadequate Cleaning of Product-Contact Surfaces

Recommendation
13/14 May 2025
GM Requirements for Planning, Qualification and Operation
In a Warning Letter, the FDA describes the inadequate cleaning of product-contact surfaces and the associated risk of cross-contamination at an Egyptian pharmaceutical manufacturer.
The FDA inspection had already taken place at the end of 2022. After reviewing the responses to the 483 report issued, the Warning Letter now followed.
According to the FDA, the manufacturer failed to include all parts of the product-contacting equipment used for the manufacture of medicinal products in the cleaning validation protocols and procedures. The aforementioned documents do not include the transport containers used for transporting medicinal products and chemical product components during manufacturing, which creates a risk of cross-contamination. The manufacturer had opened a CAPA case after the inspection and conducted a cleaning validation of the transport containers. This was not sufficient for the FDA, as it did not contain a complete assessment of all possible uses of the transport container.
Furthermore, the FDA criticised the manufacturer's incoming goods inspection. For example, the manufacturer uses ethanol (as the active ingredient), which is not checked for identity at goods receipt and is not tested for methanol content. The glycerine used is not checked for the presence of diethylene glycol (DEG) or ethylene glycol (EG). These tests are regulated in the FDA's own guidelines, as deaths have already been caused by contaminated ethanol and glycerine.
For more details please see the original FDA Warning Letter on the FDA website.
Related GMP News
05.02.2025WHO publishes Guideline on Continuous Manufacturing
29.01.2025FDA publishes Final Version of AMT (Advanced Manufacturing Technologies) Guideline
22.01.2025GMP Violations at Turkish OTC Manufacturer
15.01.2025Pharmaceutical Manufacturer obstructs FDA Inspection
11.12.2024Warning Letter to Indian Manufacturer of Sterile Ophthalmic Drop Products
06.11.2024FDA Warning Letter to a US Manufacturer of Medical Gases